Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 5:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 2,719 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Myocardial Diseases Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Clinical Decision Support Consortium

NCT00853619
View directory record Official record
Conditions
Diabetes, Coronary Artery Disease, Hypertension
Interventions
Service based decision support intervention
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Wellesley, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 29, 2012 · Synced Oct 7, 2026, 5:03 AM EDT
Withdrawn Phase 4 Interventional

L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD

NCT01855334
View directory record Official record
Conditions
End Stage Renal Disease, Hemodialysis
Interventions
Spironolactone, L-arginine, Placebo
Drug · Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 7, 2026, 5:03 AM EDT
Completed No phase listed Observational

Management of New-Onset Postoperative Atrial Fibrillation

NCT01395836
View directory record Official record
Conditions
Atrial Fibrillation, Coronary Artery Disease, Post Operative Arrythmia
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 7, 2026, 5:03 AM EDT
Completed No phase listed Observational

Efficiency and Outcomes of Stress-Only Anger and D-SPECT Stress-Only SPECT MPI

NCT01373944
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Aspire Foundation
Other
Eligibility
18 Years to 90 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Kansas City, Missouri • Lee's Summit, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 23, 2013 · Synced Oct 7, 2026, 5:03 AM EDT
Active, not recruiting Not applicable Interventional

Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment

NCT05893498
View directory record Official record
Conditions
Percutaneous Coronary Intervention
Interventions
FFRangio, FFR or NHPR
Device
Lead sponsor
CathWorks Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1,924 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
43
States / cities
La Jolla, California • Long Beach, California • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 7, 2026, 5:03 AM EDT
Completed Phase 2 Interventional

Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome

NCT00548587
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
E5555, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 80 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Beloit, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 7, 2026, 5:03 AM EDT
Not listed Phase 4 Interventional

Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting

NCT00661206
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Clopidogrel, Placebo
Drug
Lead sponsor
Deutsches Herzzentrum Muenchen
Other
Eligibility
18 Years and older
Enrollment
4,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Oct 7, 2026, 5:03 AM EDT
Enrolling by invitation No phase listed Observational

Is Our Microbiome a Predictor of Cardiac Risk

NCT02013284
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 7, 2026, 5:03 AM EDT
Completed Phase 1 Interventional

Gene Transfer Therapy for Treating Children and Adults With Limb Girdle Muscular Dystrophy Type 2D (LGMD2D)

NCT00494195
View directory record Official record
Conditions
Muscular Dystrophies
Interventions
rAAV1.tMCK.human-alpha-sarcoglycan- First cohort, Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort
Genetic
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
5 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 7, 2026, 5:03 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy

NCT05582395
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic
Interventions
Mavacamten, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 7, 2026, 5:03 AM EDT
Completed Phase 3 Interventional

A Study of the TAXUS Liberté Stent for the Treatment of Long De Novo Coronary Artery Lesions

NCT00371475
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
TAXUS Liberté-SR, TAXUS™ Express
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
19
States / cities
Sacramento, California • Newark, Delaware • Orlando, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 7, 2026, 5:03 AM EDT
Recruiting Not applicable Interventional

Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

NCT06779630
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System
Device
Lead sponsor
Teleflex
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
10
States / cities
Concord, California • Wichita, Kansas • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 7, 2026, 5:03 AM EDT
Terminated No phase listed Observational

Prognostic Assessment of Contrast Echocardiography (PACE Study)

NCT00670332
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Acusphere
Industry
Eligibility
18 Years to 80 Years
Enrollment
773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2008 · Synced Oct 7, 2026, 5:03 AM EDT
Active, not recruiting Not applicable Interventional

Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health

NCT05819814
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Disclosure of high polygenic risk result for coronary artery disease
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 7, 2026, 5:03 AM EDT
Enrolling by invitation Phase 2Phase 3 Interventional

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

NCT04848506
View directory record Official record
Conditions
Symptomatic Hypertrophic Cardiomyopathy (HCM)
Interventions
Aficamten (5 - 20 mg)
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
52
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 7, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

Study of the 2.25mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions

NCT00232739
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
CYPHER Sirolimus-eluting Coronary Stent
Device
Lead sponsor
Cordis US Corp.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2010 · Synced Oct 7, 2026, 5:03 AM EDT
Completed No phase listed Observational

Endothelial Progenitor Cells and Risk Factors for Coronary Artery Disease

NCT00013975
View directory record Official record
Conditions
Coronary Arteriosclerosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 7, 2026, 5:03 AM EDT
Terminated No phase listed Observational

Assessing Diagnostic Value of Non-invasive FFR-CT in Coronary Care in the Emergency Department

NCT05325112
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
FFR-CT
Diagnostic Test
Lead sponsor
HeartFlow, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
Worcester, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 7, 2026, 5:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Translating ATP III Cholesterol Management Guidelines Into Primary Care Practice

NCT01242319
View directory record Official record
Conditions
Hypercholesterolemia, Coronary Disease, Primary Health Care, Management, Risk
Interventions
HeartAge intervention
Behavioral
Lead sponsor
Memorial Hospital of Rhode Island
Other
Eligibility
18 Years to 80 Years
Enrollment
5,218 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Pawtucket, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 17, 2010 · Synced Oct 7, 2026, 5:03 AM EDT
Recruiting No phase listed Observational

Tezspire Cardiac Events PASS

NCT06951867
View directory record Official record
Conditions
Cardiovascular Events, MACE
Interventions
Tezepelumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
16,640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 7, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT

NCT04766892
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
mavacamten
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 7, 2026, 5:03 AM EDT
Completed Phase 3 Interventional

ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)

NCT00208299
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Regadenoson, Adenosine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2009 · Synced Oct 7, 2026, 5:03 AM EDT
Terminated No phase listed Observational

A Cardiac Disease Quality of Life Study

NCT04080492
View directory record Official record
Conditions
Hypertrophic Obstructive Cardiomyopathy, Thoracic Aortic Dilatation, Heart Disease Caused by Ionising Radiation, Quality of Life
Interventions
QOL Survey
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
380 participants
Timeline
2019 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 7, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System

NCT00307047
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
XIENCE V® Everolimus Eluting Coronary Stent, TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
3,687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
65
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Fairfax, California + 54 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Oct 7, 2026, 5:03 AM EDT